38 CHAPTER 2 REFERENCES 1. Hainsworth, J.D., et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology 36, 536-+ (2018). 2. Hyman, D.M., et al. HER kinase inhibition in patients with HER2-and HER3-mutant cancers. Nature 554, 189-194 (2018). 3. Hyman, D.M., et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. New Engl J Med 373, 726-736 (2015). 4. Colwell, J. NCI-MATCH Trial Draws Strong Interest. Cancer Discov 6, 334-334 (2016). 5. Massard, C., et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov 7, 586-595 (2017). 6. Meric-Bernstam, F., et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. Journal of Clinical Oncology 33, 2753-U2761 (2015). 7. Stockley, T.L., et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med 8(2016). 8. Hyman, D.M., Taylor, B.S. & Baselga, J. Implementing Genome-Driven Oncology. Cell 168, 584-599 (2017). 9. Le Tourneau, C., et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16, 1324-1334 (2015). 10. Prasad, V. The precision-oncology illusion. Nature 537, S63-S63 (2016). 11. Tannock, I.F. & Hickman, J.A. Limits to Personalized Cancer Medicine. New Engl J Med 375, 12891294 (2016). 12. Sleijfer, S., Bogaerts, J. & Siu, L.L. Designing Transformative Clinical Trials in the Cancer Genome Era. Journal of Clinical Oncology 31, 1834-+ (2013). 13. Ellis, L.M., et al. American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. Journal of Clinical Oncology 32, 1277-+ (2014). 14. Bins, S., et al. Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. Oncologist 22, 33-40 (2017). 15. Simon, R. Optimal 2-Stage Designs for Phase-Ii Clinical-Trials. Control Clin Trials 10, 1-10 (1989). 16. Jung, S.H., Lee, T., Kim, K. & George, S.L. Admissible two-stage designs for phase II cancer clinical trials. Stat Med 23, 561-569 (2004).
RkJQdWJsaXNoZXIy MTk4NDMw